

Supplementary Table 1. Laboratory findings during the study period

		Subject #1				Subject #2				Subject #3			
		Blood eosinophil (/mm ³)	FEV ₁ (% pred)	FeNO (ppb)	Total IgE (U/mL)	Blood eosinophil (/mm ³)	FEV ₁ (% pred)	FeNO (ppb)	Total IgE (U/mL)	Blood eosinophil (/mm ³)	FEV ₁ (% pred)	FeNO (ppb)	Total IgE (U/mL)
Mepolizumab treatment phase	V1	407				271				188			
	V2	41				30				0			
	V3	32	81		221.4	0	98		455.0	0	90		96.5
	V4	0				0				72			
	V5	0				61				58			
	V6	0	81	36	152.6	41	104	77	378.6	42	86	171	149.6
	V7	113				18				22			
	V8	90				0				80			
	V9	43	83		153.6	0	108		420.6	51	73		167.8
	V10	0				42				39			
	V11	27				51				18			
	V12	38	86	31	159.7	19	108	12	593.3	132	70	246	164.7
Follow-up phase	V13	199	78		165.0	71	107		674.4	877	78		142.7
	V14	590	83	18	182.5	461	104	N/A	454.9	752	78	178	155.4
	V15	222	92		207.6	43	113		290.3	662	68		138.8
	V16	449	89	34	160.1	333	116	N/A	252.9	972	72	128	175.3

FEV₁, forced expiratory volume in 1 second; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E; V, visit; N/A, not available.